Fish oil-based drug Vascepa (icosapent ethyl) could make a smaller splash than Amarin (Nasdaq: AMRN) had hoped, after a US court nixed part of its patent estate.
In pre-market trading, shares in the company plummeted nearly 70%.
Asserting the claims were “invalid as obvious,” a district court judge in Nevada ruled that six patents, due to expire in 2030, were invalid.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze